Phospholipid Metabolites in Recurrent Glioblastoma: In Vivo Markers Detect Different Tumor Phenotypes Before and Under Antiangiogenic Therapy

PLoS ONE - United States
doi 10.1371/journal.pone.0056439
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

Antiangiogenic Therapy for Glioblastoma: Current Status and Future Prospects

Clinical Cancer Research
Cancer ResearchOncology
2014English

Commentary: Pitfalls in the Neuroimaging of Glioblastoma in the Era of Antiangiogenic and Immuno/Targeted Therapy

Frontiers in Neurology
Neurology
2018English

Antiangiogenic Agents in the Treatment of Recurrent or Newly Diagnosed Glioblastoma: Analysis of Single-Agent and Combined Modality Approaches

Radiation Oncology
Nuclear MedicineRadiologyImagingOncology
2011English

Antiangiogenic Therapy: A Novel Approach to Overcome Tumor Hypoxia

Chinese Journal of Cancer
2010English

Clonal Evolution of Glioblastoma Under Therapy

Nature Genetics
Genetics
2016English

Antiangiogenic Agents in Cancer Therapy

Journal of the Royal Society of Medicine
Medicine
1999English

Antiangiogenic Therapy

BMC Geriatrics
GerontologyGeriatrics
2010English

Antiangiogenic Therapy in Breast Cancer

Memo - Magazine of European Medical Oncology
OncologyHematology
2017English

Antiangiogenic Therapy Using Bevacizumab in Recurrent High-Grade Glioma: Impact on Local Control and Patient Survival

Journal of Neurosurgery
SurgeryNeurology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy